

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)



(10) International Publication Number
WO 2022/186772 A1

(51) International Patent Classification:

A61P 17/00 (2006.01) A61K 39/395 (2006.01)
A61P 37/00 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/SG2022/050102

(22) International Filing Date:

01 March 2022 (01.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202102086S 01 March 2021 (01.03.2021) SG
10202110688T 27 September 2021 (27.09.2021) SG

(71) Applicant: ASLAN PHARMACEUTICALS PTE LTD

[SG/SG]; 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920 (SG).

(72) Inventors: VEVERKA, Karen A.; c/o Aslan Pharmaceuticals Pte Ltd, 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920 (SG). WARD, Alison; c/o Aslan Pharmaceuticals Pte Ltd, 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920 (SG).

(74) Agent: STERLING IP PTE LTD; 10 Anson Road, #29-09 International Plaza, Singapore 079903 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13R α 1 ANTIBODY OR BINDING FRAGMENT THEREOF

(57) Abstract: An antibody, antigen binding fragment thereof or a pharmaceutical formulation, which is an inhibitor of signalling through IL-13R α 1 by binding said receptor and compositions comprising the same for use in the treatment of atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200mg to 600mg, (such as 400 to 600mg), wherein the disease is modified by a percentage reduction in EASI score in the range - 20 to -100 % from the baseline.

WO 2022/186772 A1